Test Code: 12346

References

  1. Gene IDH1. COSMIC: Catalogue Of Somatic Mutations In Cancer. V97. Accessed March 15, 2023. https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IDH1
  2. Gene IDH2. COSMIC: Catalogue Of Somatic Mutations In Cancer. V97. Accessed March 15, 2023. https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IDH2
  3. Cuervo-Sierra J, Jaime-Pérez JC, Martínez-Hernández RA, et al. Prevalence and clinical significance of FLT3 mutation status in acute myeloid leukemia patients: a multicenter study. Arch Med Res. 2016;47(3):172‐179. doi:10.1016/j.arcmed.2016.06.003
  4. Megías-Vericat JE, Ballesta-López O, Barragán E, et al.  IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood Lymphat Cancer. 2019;9:19-32. doi:10.2147/BLCTT.S177913
  5. Amaya, ML and Pollyea, DA. Targeting the IDH2 pathway in acute myeloid leukemia. Clin Cancer Res. 2018:24(20):4931-4936. doi:10.1158/1078-0432.CCR-18-0536
  6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009:360(8):765-773. doi:10.1056/NEJMoa0808710
  7. Pabst T, Eyholzer M, Fos J, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with a favourable prognosis. Br J Cancer. 2009:100(8):1343-1346. doi:10.1038/sj.bjc.6604977
  8. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006:24(24):3904-3911. doi:10.1200/JCO.2006.06.9500
  9. Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther. 2009:9(9):1283-1294. doi:10.1586/era.09.84
  10. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012:119(9): 2114-2121. doi:10.1182/blood-2011-08-375758
  11. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96-102. doi:10.1016/S1525-1578(10)60458-8
  12. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434-2439. doi:10.1182/blood.v97.8.2434

 

This FAQ is provided for informational purposes only and is not intended as medical advice. Test selection and interpretation, diagnosis, and patient management decisions should be based on the clinician’s education, clinical expertise, and assessment of the patient.

 

Document FAQS.260 Version: 0

Version 0: Effective 08/28/2023 to present